WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of ...
For decades, therapeutic monoclonal antibody (mAb) production relied on traditional batch-based manufacturing using stainless steel systems. But as biopharmaceutical pipelines grow to meet rising ...
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have ...
WALTHAM, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into an ...
We are thrilled to partner with Repligen to accelerate our customers’ path to the clinic and enable successful commercialization of innovative exosome therapies.” — Tim Kelly, Chief Executive Officer ...
With the precision of monoclonal antibodies and the potency of small-molecular payloads, antibody-drug conjugates (ADC) are promising cancer therapeutics. As of this year, there are 19 ADC drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results